Drug · CHEMBL518924
MAVORIXAFOR
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. MAVORIXAFOR. Drugs and targets, record CHEMBL518924. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL518924
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- AMD-070, AMD-11070, AMD070, AMD11070, Amd 070, Cxcr4 inhibitor x4p-001, X 4P-001, X4P-001, X4p001, Xolremdi
- ChEMBL
- Open Targets' highest stage
- Approval, for 2 of its 11 diseases, from ATC and EMA Human Drugs
- Open Targets
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| CXCR4 | C-X-C chemokine receptor type 4 | C-X-C chemokine receptor type 4 antagonist | ANTAGONIST | https://conductscience.org/library/genes/7852 |
Source ChEMBL
Diseases11
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 11Source Open Targets
See all 11 diseasesTrials15
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT02667886 | Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma | Phase 1/2 | 74 | 2024-08-14 | x4p-001 | Its name | ClinicalTrials.gov |
| NCT02923531 | Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma | Phase 1/2 | 9 | 2022-12-29 | mavorixafor | Its name | ClinicalTrials.gov |
| NCT03005327 | A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome | Phase 2 | 8 | 2024-10-30 | mavorixafor | Its name | ClinicalTrials.gov |
| NCT06056297 | A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections | Phase 3 | 176 | mavorixafor | Its name | ClinicalTrials.gov | |
| NCT00063804 | Safety of AMD070 When Administered Alone or Boosted With Low-Dose Ritonavir in HIV Uninfected Men | Phase 1 | 44 | amd070 | Its name | ClinicalTrials.gov | |
| NCT06858696 | A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | Phase 1 | 39 | mavorixafor | Its name | ClinicalTrials.gov | |
| NCT06914869 | Drug-Drug Interaction Potential of Mavorixafor | Phase 1 | 38 | mavorixafor | Its name | ClinicalTrials.gov | |
| NCT04154488 | A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders | Phase 1/2 | 32 | mavorixafor | Its name | ClinicalTrials.gov | |
| NCT03995108 | Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome | Phase 3 | 31 | mavorixafor | Its name | ClinicalTrials.gov | |
| NCT05103917 | A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC | Phase 1/2 | 24 | X4P-001 | Its name | ClinicalTrials.gov |
1 to 10 of 15
See all 15 trialsComparisons in its trials0
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
None in this release.
Papers from its trials7
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL518924
GET https://conductscience.org/api/drugs/v1/CHEMBL518924/targets